Morris Plains, NJ, June 14, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibodybased products for the targeted treatment of cancer, autoimmune and other serious ...

Vancouver, BC, June 10, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody- based products for the targeted treatment of cancer, autoimmune and other serious ...

Morris Plains, NJ, May 30, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody- based products for the targeted treatment of cancer, autoimmune and other serious ...

COMBINATION OF 90Y-EPRATUZUMAB AND VELTUZUMAB IS ACTIVE IN NON-HODGKIN LYMPHOMA -- Results on Potential New Treatment Regimen Presented at SNMMI 2013 Annual Meeting -- Vancouver, BC, June 11, 2013 --- Immunomedics, Inc.

90Y-EPRATUZUMAB STUDY SHOWS IMPROVEMENT OF THERAPY RESULTS FOLLOWING R-CHOP Vancouver, BC, June 10, 2013 --- Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of ...

Clearwire Corporation (NASDAQ:CLWR) shares jumped 29.31% to $4.50. The company on May 30 acknowledged that DISH Network Corporation (NASDAQ: DISH) (�DISH�) has commenced an unsolicited cash tender offer to acquire all outstanding common ...

Immunomedics Inc. (NASDAQ:IMMU) a biopharmaceutical company that engages in the research, development, manufacture, and marketing of monoclonal, antibody-based products for the treatment of cancer, autoimmune, and other serious diseases in the ...

[ClickPress, Mon May 27 2013] Global Market Direct's pharmaceuticals report, "Immunomedics, Inc. - Product Pipeline Review - 2013" provides data on the Immunomedics, Inc.'s research and development focus. The report includes information on current ...

Immunomedics Inc. (NASDAQ: IMMU) is on the radar screen as a possible option trade candidate. Immunomedics is a biopharmaceutical company engaged in the research, development, manufacture and marketing of monoclonal, antibody-based products ...

It's been reported Celsion Corporation (NASDAQ:CLSN) announced that it has received commitments from institutional investors to buy an aggregate of $9.83 million of the Company's common stock, in an at-the-market registered direct offering, which was ...